Hlas

Slovakia may be about to elect a government which plans to halt aid to Kyiv

Retrieved on: 
Thursday, September 28, 2023
People, SNS, Social democracy, Slovak National Party, PS, Hlas, Policy, Christian Democratic Movement, Christian democracy, COVID, Government, Human voice, Progressive Slovakia, Democracy, Population, Democrat, Refugee, SAS, Voice – Social Democracy, Family, KDH, Arms industry, Convenience food, Cryptocurrency, EU, Direction – Slovak Social Democracy, Fico, Solidarity

After the outbreak of the illegal Russian war in Ukraine, Slovakia was one of the first states to offer support to its neighbour.

Key Points: 
  • After the outbreak of the illegal Russian war in Ukraine, Slovakia was one of the first states to offer support to its neighbour.
  • Slovakians warmly welcomed Ukrainian refugees and its coalition governments have staunchly maintained political, economic and military aid for Kyiv.
  • The key for both sides is being able to put together a stable enough coalition to form government, and here’s where it gets complicated.

Pro-Kyiv bloc

    • When it comes to the war in Ukraine, the pro-Kyiv bloc is a coalition of parties with very different ideologies which could find it hard to form a stable government.
    • Another pro-Ukrainian party is Ordinary People and Independent Personalities (Olano), a populist centre-right, anti-establishment party which is polling at 9.4%.
    • But the prospects of PS having the numbers to form a working coalition are far from certain as the campaign goes into its final day.

Anti-Ukraine bloc

    • Smer and its leader, Fico, supports Slovakia’s membership of the EU and Nato, but is opposed to allowing Ukraine to join either alliance.
    • The party has said it would halt economic and military support to Ukraine.
    • But Hlas, which is polling at 15%, is opposed to forming a coalition with extreme right-wing parties.

Danger signs for Kyiv

    • As it stands, Slovakia may be the first country to change its policy and stop supporting Ukraine.
    • But there are signs other countries could follow suit.

TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

Retrieved on: 
Monday, January 23, 2023
Food, Melanoma, Safety, IND, Large-cell lung carcinoma, TCR, Cancer, MAGE-A1, Cervical cancer, Patient, Ovarian cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, HLA, Neoplasm, Head, Therapy, Hlas, Vaccine, Pharmaceutical industry, Interkom Kom Ind

WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) --  TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) applications for T-Plex, TSC-204-A0201, and TSC-204-C0702.

Key Points: 
  • Each unique TCR-T will be filed as a secondary IND and will reference the primary T-Plex IND.
  • MAGE-A1 is a cancer-associated antigen overexpressed in 45% of head and neck cancers and 50% of melanoma, cervical, and non-small cell lung cancers.
  • TScan believes that TSC-204-C0702 is the first clinical program in MAGE-A1 for an HLA type other than A*02:01.
  • With the FDA clearance of T-Plex, along with two MAGE-targeting TCRs, we are now one step closer to bringing bespoke cell therapies to patients.

Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023

Retrieved on: 
Monday, January 9, 2023
IND, Hlas, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Tumor microenvironment, TCR, Sleeping Beauty, Food, Survival, Patient, EGFR, Research, TP53, Clinical trial, Pharmaceutical industry

Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platform

Key Points: 
  • Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platform
    HOUSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today highlights its expected milestones and strategic priorities for 2023.
  • The year ahead will focus on increasing patient enrollment with an aim towards advancing the program to Phase 2 readiness.
  • Based on current operating plans, the Company expects its operating cash flow for 2023 to be between approximately $35 million and $40 million.
  • The Company expects to have sufficient cash resources to fund research and development programs and operations into Q4 2023.

TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

Retrieved on: 
Thursday, January 5, 2023
Cancer, Immunotherapy, Head, TCR, Therapy, Society for Immunotherapy of Cancer, SITC, Lymphatic system, IND Crosstown Line, MBA, CPA, Growth, Patient, Hlas, PRAME, MAGE-A1, IND, HPV, Neoplasm, Pharmaceutical industry, Vaccine, Medical imaging, Finance

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced its 2023 clinical pipeline plans and highlighted recent corporate achievements.

Key Points: 
  • “We made significant progress and growth in 2022, positioning both our solid tumor and hematologic malignancies programs for important data readouts in 2023,” said David P. Southwell, President and Chief Executive Officer.
  • “Our solid cash runway funds us well into 2024, seeing us through to multiple value-generating milestones.
  • We believe that 2023 will be a pivotal year for TScan as we continue to advance our industry-leading clinical stage portfolio of TCR-T therapy candidates in both our solid tumor and hematologic malignancies programs.”
    Debora Barton, M.D., Chief Medical Officer added, “We look forward to multiple clinical milestones next year.
  • The Company expects to report initial multiplex therapy data for this program in 2024

PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022

Retrieved on: 
Friday, December 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Memory, Peptide, Melanoma, Blood bank, PBMC, HLA-A2, B cell, Antigen, Large-cell lung carcinoma, NK, Poster, MUC1, Patient, NY-ESO-1, PDC, Lung cancer, Hlas, GMP, Non-small-cell lung carcinoma, PD-1, RECIST, White blood cell, Safety, Cancer, Dendritic cell, ESMO, Human, RNA transfection, LOQ, Clinical trial, Growth, Bioreactor, MAGE, EFS, Pembrolizumab, Mutation, Pharmaceutical industry, Vaccine, NSCLC

The preliminary data was presented today at a poster display session at the ESMO Immuno-Oncology Congress 2022 (ESMO-IO) in Geneva (Switzerland).

Key Points: 
  • The preliminary data was presented today at a poster display session at the ESMO Immuno-Oncology Congress 2022 (ESMO-IO) in Geneva (Switzerland).
  • The objectives of the phase I/II trial (PDC-LUNG-101) are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients.
  • It is administered weekly by a subcutaneous and intravenous route, in six consecutive doses.
  • Safety and clinical activity of the product were presented at ESMO 2022 in September 2022 in Paris (France).

Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation

Retrieved on: 
Thursday, December 8, 2022
NIH, Immunoglobulin G, Kidney transplantation, Dialysis, ESRD, European Medicines Agency, Italian Medicines Agency, EMA, Patient, Cancer, DSA, Research, Hlas, Nasdaq Stockholm, Kidney disease, Degenerative disease, Medicine, Human leukocyte antigen, Veni, vidi, vici, Antibody, Survival, Kidney, Hansa, Medication package insert, State, Safety, Kidney failure, European, Chronic kidney disease, European Marketing Research Centre, Transplant, Risk, Dentistry, Pharmaceutical industry, Medical device, Agency

The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix to enable kidney transplantation.

Key Points: 
  • The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix to enable kidney transplantation.
  • By the time the body starts to synthesize new IgG, the patient will be receiving post transplant immunosuppressive therapy to reduce the risk of organ rejection.
  • Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022
Breast, Blood, Administration, EGFR, TCR, Telephone, Biotechnology, Poster, Toxic shock syndrome toxin, Risk, Research and development, KRAS, Mutation, Therapy, TP53, Conference, SITC, Research, Investigational New Drug, Safety, Progression-free survival, Security (finance), Society, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ID, Intellectual property, Hlas, Development, Cash, State Administrative Expenses, NSCLC, Receptor, National Cancer Institute, Immunotherapy, Colorectal cancer, Food, Patient, Sleeping Beauty, Pharmaceutical industry, Vaccine

Third Quarter Ended September 30, 2022 Financial Results

Key Points: 
  • Third Quarter Ended September 30, 2022 Financial Results
    Collaboration Revenue: Collaboration revenue was $2.9 million for the third quarter of 2022, compared to $0.4 million for the third quarter of 2021, an increase of 631%.
  • Research and Development Expenses: Research and development expenses were $7.9 million for the third quarter of 2022, compared to $14.5 million for the third quarter of 2021, a decrease of approximately 46%.
  • Cash and Cash Equivalents: As of September 30, 2022, Alaunos had approximately $37.8 million in cash and cash equivalents and restricted cash of $13.9 million.
  • Operating cash burn for the third quarter of 2022 was $6.1 million compared to $9.6 million in the third quarter of 2021, a decrease of $3.4 million or 36%.

North America Human Leukocyte Antigen Testing Market Report 2022: Rising Government Funding for Organ Donation Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, November 18, 2022
Biotechnology, General Health, Health, Prevalence, Arrest, Transplant, Holm–Bonferroni method, Organ transplantation, Organ, Hlas, Protein, OPTN, Manifest and latent functions and dysfunctions, DCD, Conditional sentence, COVID-19, HLA, Kidney failure, Patient, Vaccine, Dentistry

The "North America Human Leukocyte Antigen Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product and service, Technology, and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Human Leukocyte Antigen Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product and service, Technology, and End User" report has been added to ResearchAndMarkets.com's offering.
  • Human leukocyte antigens (HLAs) are specialized proteins present on all cell surfaces of the human body except red blood cells.
  • The growing prevalence of chronic diseases and organ failure leads to high demand for organ transplant procedures, as well as HLA testing.
  • This factor is likely to drive the north america human leukocyte antigen (HLA) testing market at a notable CAGR during the forecast period.

TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 9, 2022
Umbrella, IND, HCT, Immunotherapy, Research, Therapy, Microdeletion syndrome, MAGE-A1, Securities Exchange Act of 1934, Company, MDS, Novartis Institute for Tropical Diseases, Review, Biomedical Research, Annual general meeting, Food, Society, Hand, Society for Immunotherapy of Cancer, Collection, Cancer, PRAME, AML, Patient, Analysis, Result, ASH, COVID-19, Private Securities Litigation Reform Act, TCR, Nasdaq, Acute myeloid leukemia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lymphatic system, Hlas, ALL, HLA, Clinical trial, Acute leukemia, Growth, IND World's Fair Line, FDA, Trial of the century, GLOBE, Haematopoietic system, Financial condition report, HPV, Annual report, Safety, RIC, Multiplexing, SITC, Pharmaceutical industry, Vaccine, Food delivery

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results and provided a business update for the third quarter ended September 30, 2022.

Key Points: 
  • The initial $30 million that we drew at the close provides TScan with a cash runway into the second quarter of 2024.
  • During the quarter TScan announced the closing of a convertible debt facility for up to $60 million with K2 HealthVentures (K2HV).
  • As of September 30, 2022, TScan Therapeutics had cash and cash equivalents of $137.3 million, excluding $5.0 million of restricted cash.
  • For the third quarter ended September 30, 2022, TScan Therapeutics reported a net loss of $16.2 million, compared to a net loss of $15.8 million for the 2021 Quarter.

PACT Pharma Reports Data From First Clinical Study Using CRISPR to Substitute a Gene in Patients' Immune Cells to Treat Cancer

Retrieved on: 
Thursday, November 10, 2022
SAN, Fever, Confusion, TCR, Moore v. Regents of the University of California, Immunotherapy, Research, Colon, Neoplasm, Technology, Lung cancer, Gene, PACT, Medicine, Patient, Hlas, Safety, CRISPR, Breast, HLA, Cancer, Chills, Clinical trial, University, Immune system, Society, Blood, SITC, Trial of the century, Vaccine, Medical imaging, Nature

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 /PRNewswire/ -- PACT Pharma, Inc., a privately held biopharmaceutical company developing transformational personalized neoantigen-specific and off-the-shelf T cell receptor (TCR)-T cell therapies for the eradication of solid tumors, today reported data from the first clinical study using CRISPR gene editing technology to substitute a gene in patients' immune cells to treat cancer. Results from the study, which was conducted with collaborators at nine academic centers using PACT's proprietary platforms, demonstrated early proof-of-concept that a patient's immune system can be reprogrammed to recognize their own cancer. The study findings were the focus of a late breaking oral presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022), as well as a peer-reviewed paper in Nature that was published in conjunction with SITC 2022.

Key Points: 
  • Every patient's immune system contains T cells that can utilize specific receptors to find and kill cancer cells.
  • Unfortunately, patients often do not have enough of these T cells to mount a complete and effective attack on their cancer.
  • Once infused back into the patient, these engineered T cells redirect the patients' immune system to recognize the patient's own cancer.
  • The study involved researchers using patients' blood samples to directly isolateT cells targeting mutations related to each patient's cancer.